Index of artpub/2023/296632/

Escudero-Vilaplana, V
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
2023
https://ddd.uab.cat/record/296632